HDFC Pharma and Healthcare Fund
NAV
₹21.99
as of 6 Oct 2026
HDFC Pharma and Healthcare Fund is an open-ended Sectoral/ Thematic scheme from HDFC Mutual Fund managing ₹3,311 crore (as of 31 Aug 2026). Its Direct-plan NAV is ₹21.99 as of 6 Oct 2026. The expense ratio is 1.08% a year. Managed by Dhruv Muchhal. This page is factual data only – it carries no rating and no recommendation.
Key facts
- Expense ratio
- 1.08% / yr
- as of 31 Aug 2026
- Fund size
- ₹3,311 crore
- as of 31 Aug 2026
- Exit load
- 1%
- SIP available
- Yes
- Launched
- 4 Oct 2023
- ISIN
- INF179KC1HO1
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from nyvo’s own NAV data.
Rebased to 100data to 5 Oct 2026Benchmark: Nifty 500 Healthcare TRI
HDFC Pharma and Healthcare Fund
₹219
+119% on ₹100 over 3.0 yrs
Sectoral/ Thematic average
₹176
+76% on ₹100 over 3.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | 2.62% | – | – |
| 6 months | 22.69% | – | – |
| 1 year | 24.78% | – | – |
| 3 years (CAGR) | 29.73% | – | – |
No category average is available for this fund. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible – read that number first.
1-year holding periods
- Worst
- 1.7%
- Median
- 22.4%
- Best
- 67.0%
25 windows over the last 36 months, stepped monthly; 100% ended positive. Worst window began 1 Jan 2025. Windows overlap – this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 30.2%
- Median
- 30.2%
- Best
- 30.2%
1 windows over the last 36 months, stepped monthly; 100% ended positive. Worst window began 4 Oct 2023. Windows overlap – this is the range of past start dates, not a probability of anything.
Distance below its own peak
Every dip below 0 is the fund trading under a previous high – how deep and for how long is what a drawdown feels like.
Right now
-4.9% below peak
Where the money actually is
Equity
98.4%
Cash
1.6%
Whole-portfolio split, as of 31 Aug 2026.
What it owns
41 positions · top 10 = 48.9%
Market-cap mix
Large 27.9%Mid 33.2%Small 34.4%Other 4.5%
as of 31 Aug 2026
Holdings by sector
Healthcare(9 in top 10)95.2%
- Divi's Laboratories Ltd9.54%
- Sun Pharmaceuticals Industries Ltd8.94%
- Torrent Pharmaceuticals Ltd4.08%
- Max Healthcare Institute Ltd Ordinary Shares4.06%
- Lupin Ltd4.04%
- Cipla Ltd3.94%
- Aster DM Quality Care Ltd Ordinary Shares3.84%
- Neuland Laboratories Ltd3.70%
- Anthem Biosciences Ltd3.48%
Basic Materials(1 in top 10)3.2%
- Acutaas Chemicals Ltd3.24%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Aug 2026. Portfolio turnover 38.2% a year.
The businesses it owns
- P/E (trailing)
- 45.2
- P/B
- 7.0
- Dividend yield
- 0.5%
- Net margin
- 16.4%
- Earnings growth
- 16.1%
- Avg market cap
- ₹63,799 crore
Money in, money out
- Net flow, 12 months
- +₹807 cr
- Net flow, 3 months
- +₹620 cr
as of 31 Aug 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of HDFC Pharma and Healthcare Fund?
- ₹21.99 per unit as of 6 Oct 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of HDFC Pharma and Healthcare Fund?
- 1.08% a year for the Direct plan, as of 31 Aug 2026.
- How large is HDFC Pharma and Healthcare Fund?
- ₹3,311 crore under management as of 31 Aug 2026, in the Sectoral/ Thematic category.
- How risky is HDFC Pharma and Healthcare Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What is the worst 3-year return of HDFC Pharma and Healthcare Fund?
- 30.2% a year – the weakest of 1 overlapping 3-year holding periods, beginning 4 Oct 2023. The median was 30.2% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages HDFC Pharma and Healthcare Fund?
- Dhruv Muchhal, managing this fund for 2.9 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund – growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹38,338 crore
- ICICI Prudential Business Cycle Fund₹15,873 crore
- HDFC Defence Fund₹11,478 crore
- HDFC Manufacturing Fund₹10,752 crore
- Kotak Business Cycle Fund₹3,509 crore
- Mirae Asset Healthcare Fund₹3,442 crore
- Tata Banking & Financial Services Fund₹3,301 crore
- Aditya Birla Sun Life MNC Fund₹3,293 crore
Data: nyvo research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty 500 Healthcare TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.